Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 13Breast Neoplasms, Male 3Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Carcinoma, Intraductal, Noninfiltrating 2Recurrence 1Pancreatic Cyst 1Osteosarcoma 1Inflammatory Breast Neoplasms 1Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer 1Glioblastoma 1Gastrointestinal Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Carcinoma In Situ 1Brain Neoplasms 1Advanced Cancer 1

Interventions

Temozolomide 38Radiotherapy 22Radiosurgery 22Radiation 11Magnetic Resonance Spectroscopy 11Irinotecan 11Cyclophosphamide 11Etoposide 10Surgical Procedures, Operative 9Erlotinib Hydrochloride 9Carmustine 9pembrolizumab 8Filgrastim 8Carboplatin 8Bevacizumab 7Vincristine 6Sorafenib 6O(6)-benzylguanine 6Nivolumab 6Flucytosine 6Aminolevulinic Acid 6temsirolimus 5sargramostim 5Vorinostat 5Trastuzumab 5Topotecan 5Lomustine 5Imatinib Mesylate 5Granulocyte Colony-Stimulating Factor 5Everolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Brain Neoplasms × Tamoxifen × Clear all
NCT04200066 2022-08-22

A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma

University of Rochester

Phase 1 Withdrawn
CNS

Brain Neoplasms, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡